Disphanurat W, et al. - In this randomized evaluator‐blind trial, researchers compared the effectiveness and safety of 0.15% isobutylamido thiazolyl resorcinol (ITR) plus hyaluronic acid (HA) vs 0.15% ITR or HA alone in melasma treatment. For 12 weeks, 92 patients were given ITR 0.15% plus HA (n = 30), 0.15% ITR (n = 31), or HA (n = 31), as well as broad‐spectrum sunscreen application. According to findings, melasma severity was effectively decreased by a combination of 0.15% ITR and 0.15% ITR+HA. HA could improve melasma homogeneity synergistically.